Loading...
•
Sep 30, 2023
Omeros Q3 2023 Earnings Report
Announced financial results for the third quarter ended September 30, 2023, with a net loss of $37.8 million and OMIDRIA royalties of $10.0 million.
Key Takeaways
Omeros Corporation reported a net loss of $37.8 million for Q3 2023, compared to a net loss of $17.5 million in the prior year quarter. OMIDRIA royalties were $10.0 million, down from $16.5 million in the prior year quarter due to a decrease in the royalty rate. The company had $310.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023.
Net loss was $37.8 million, or $0.60 per share, compared to a net loss of $17.5 million, or $0.28 per share, in the prior year quarter.
OMIDRIA royalties were $10.0 million on Rayner Surgical’s U.S. net sales of $33.3 million, compared to $16.5 million in the prior year quarter on U.S. net sales of $33.0 million.
Cash burn for the quarter was $31.0 million.
The company expects an FDA approval decision on its resubmitted BLA for narsoplimab in TA-TMA in mid-2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...